

Original Article

Cloning of Rota Virus Outer Capsid Protein (VP7) Gene into the pGEM Vector

Khodabandehloo M¹, Shamsi-Shahrabadi M^{1*}, Bambai B²

1. Virology Department, Tehran University of medical sciences, Tehran, Iran.

2. National Research Center of Genetic Engineering and Biotechnology, Tehran, Iran.

Abstract

Background and Aims: In humans the group A rotaviruses are associated with endemic diarrhea in children under the age of 5, leading to approximately 800,000 deaths every year. Introduction of rotavirus vaccines into childhood immunization programs can contribute to substantial reduction in mortality from rotavirus gastroenteritis in developing countries and virtually eliminating hospitalizations due to rotavirus gastroenteritis, a heavy burden in developed countries. A reassortant Rhesus-human rotavirus vaccine, Rotashield was manufactured and marketed in 1998. Nine months later a small number of cases of intussusceptions were identified, leading to the withdrawal of vaccine. Important questions remain for these oral live vaccines related with safety and side effects as well as production costs, thus development of second generation of nonreplicating rotavirus vaccine should be considered as an alternative to live vaccines. VP7 is major outer capsid glycoprotein; can induce production of neutralizing antibodies. Regarding these concepts we cloned VP7 gene of SA11 rotavirus in pGEM vector for future expression.

Methods: With large scale expression and purification of VP7 protein, it will be convenient to study VP7 antigenic, immunogenic, biologic functions and its potential for vaccine development.

Results: BSC-1 cells were grown as a monolayer. Simian rotavirus, SA11 was cultured. Oligonucleotide forward and reverse primers, specific for gene segment 9 which encodes VP7, were synthesized, according to dsRNA gene segment 9 of simian rotavirus SA11 sequence data at NCBI GeneBank. Rotavirus ds-RNA was extracted and used as template for reverse transcription to synthesize cDNA from both viral strands. cDNA product of RT-PCR was cloned into pGEM@-5Zf(-) vector and the results showed that rotavirus genome segment 9 was cloned into pGEM@-5Zf(-) vector and confirmed by restriction enzyme and sequencing.

Conclusion: Sequencing result was analyzed by BLAST software showing 100% homology with 9¹ SA11 rotavirus genome segment in NCBI GeneBank.

Keywords: Rotavirus; VP7; cloning

Introduction

***Corresponding author:** Mahmoud Shamsi-Shahrabadi PhD, Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Tel/Fax: (+98) 21 88 60 22 05

Email: Mshahrabadi@hotmail.com

Rotaviruses are members of family Reoviridae. The mature rotavirion is an icosahedron consisting of three concentric shells of protein that surround a genome of eleven segments of double-stranded RNA (ds-RNA). This genome codes for six structural

proteins (VPI-VP4, VP6 and VP7) and six nonstructural proteins (NSPI-NSP6) (6, 8, 10). VP4 is an unglycosylated protein and forms dimeric spikes which in combination with VP7 constitute outer layer of viral capsid protein. Moreover, VP4 has been shown to be a determinant of several important functions, such as cell attachment, entry to cells, hemagglutination, and neutralization (3, 6, 9, 10). Epitopic-specific antibodies to VP4 and VP7 correlate with protecting from infection; however, there is conflicting arguments about the role these antibodies in protection (1, 3, 6, 8, 10).

Rotaviruses are causative agents of diarrheal diseases in a wide variety of mammalian animals. In humans the group A rotaviruses are associated with endemic diarrhea in children under the age of 5 year (8, 13, 14). Because of the significant burden of rotavirus disease among children and animals worldwide, considerable efforts have been devoted towards the development of vaccines for disease prevention and control (8, 9, 12). Nevertheless, host susceptibility and immunity to severe rotavirus-induced diarrhea are not fully understood. The role of homotypic and heterotypic immune responses in protection against disease is still controversial despite its relevance to vaccine development (3, 7, 8). Introduction of rotavirus vaccines into childhood immunization programs can contribute to substantial reduction in mortality from rotavirus gastroenteritis (12, 14).

A reassortant rhesus-human rotavirus vaccine, Rotashield was manufactured and licensed by Wyeth Lederle and went into national use in the United States in 1998. Nine months later a small number of cases of intussusceptions were identified, leading to the withdrawal of vaccine (12). Other manufacturers have gone on to develop alternative live oral vaccines (6, 10, 14). Development of second generation of non-replicating rotavirus vaccine is being considered as an alternative to live vaccines. Virus like particles constitutes a potential alternative approach (5, 14). Regarding these concepts we cloned VP7 gene of SA11 rotavirus into pGEM vector for future expression in suitable host (15). The protein obtained in

large scale can be tested for vaccine developments.

Methods

Cell and virus culture

African green monkey kidney fibroblastic cell line, BSC-1, was grown as monolayer in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, 2mM L-glutamine, 100 U of penicillin and 100 ug of streptomycin per ml. Simian rotavirus SA11 was treated with 10 ug/ml trypsin for 60 min at room temperature to activate virus infectivity, then, propagated in BSC-1 cells using serum free medium supplemented with 0.5 ug/ml trypsin. When infected cells showed 80% rotavirus cytopathic effect, cultured flasks were harvested by freeze-thawing three times and clarified by low speed centrifugation. The virus was concentrated by ultra-centrifugation on 40% sucrose cushion, at 20000 rpm for 2 h.

Electron microscope

A grid prepared from concentrated virus was stained with 2% phosphotungstic acid, then, examined in electron microscope.

RNA extraction

RNA was extracted from viral pellet by RNAfast RNA extraction reagent, manufactured in National Research Center for Genetic Engineering and Biotechnology (NRCGEB), according to manual. Extracted RNA was electrophoresed on 10% polyacrylamide (PAGE). RNA bands were identified by staining with ethidium bromide.

Primer designing

Oligonucleotide primers specific for genome segment no 9, which encodes VP7, were designed and synthesized from simian rotavirus SA11 sequence data at NCBI GeneBank (accession number K02028) (2), forward (from nucleotide no 47 to 72) and reverse (from nucleotide no 1006 to 1029). The nucleotide sequences of the primers were as follow: VP7 Forward primer (VP7-F2): 5' ت TAA TGT ATG GTA TTG AAT ATA CCA CA- 3', and VP7 reverse primer (VP7-R2): 5' ت GCA GCA TTT TAT TAC AGA GTG TAG- 3'.

cDNA synthesis

Rotavirus ds-RNA was used as template to synthesize cDNA copies from both viral strands. Reverse transcription reaction was carried out using a mixture of 10 ul dsRNA template, 1 ul of 100 uM of each of the primers. The reaction tubes were heated at 95 DC for 5 min and quickly cooled at 4 DC, then the reverse transcription mixture consisting of 5X incubation buffer, 1 ul of 2.5 mM dNTPs mix, 20U/-11 of RNase inhibitor (Fermentas) and 40 U of M⁻MuL Virus reverse transcriptase (Roche) were added to total volume of 20 ul and the tubes were incubated in a thermo cycler at 37 DC for 60 minutes.

PCR amplification

PCR reaction was carried out in total volume of 50 ul containing: 5 ul of cDNA synthesis reaction, 5 ul of 10X PCR buffer, 1 ul of 20/-1M of primers, 4 ul of 10mM dNTPs mix, and 2.5 U of pfu DNA polymerase (Fermentas). Incubation program was an initial denaturation at 95 DC for 5 min, followed by 95 DC for 30 sec, 60 DC for 30 sec and 72 DC for 2 min for total of 35 cycles with final extension time at 72 DC for 10 min. Final product was electrophoresed in 1 % agarose gel.

Verification of RT-PCR product

The amplicon obtained was verified by agarose gel electrophoresis and purified by PCR product purification kit (Roche). PCR product of genome segment 9 was verified primarily by molecular weight and restriction enzyme DdeI digestion of amplicon (Roche).

Ligation

PCR product was introduced into the *EcoRV* cut pGEM⁺5Zf(-) vector (Promega) by direct blunt end ligation overnight at room temperature according to manual of T4 DNA ligase (Roche). Resulting plasmid, named VP7s-pGEM, was used to transform competent DRS-a, Ecoli cells.

Preparation of competent cells & Transformation

Transformation of competent DR5-cells was performed according to the method of Mandel & Riga (11). Briefly, two ul of plasmid or ligation reaction was added to 100 ul fresh competent cells and incubated in ice for 30 min. The cells were incubated at 42⁰ C for 1

min and immediately kept in ice for 30 min. The cells were suspended in 900 ul of LB broth and agitated for 1 h at 37 DC. Then 50 ul of the suspension was spread on agar plate containing ampicillin.

Colony screening

The clones were selected in LB agar plates, supplemented with 50 ug/ml ampicillin, 40 ul of 2% x-gal and 7 ul of 20% IPTG. Final screening was carried out by digestion of Miniprep plasmids (Plasmid extraction kit, Roche) with *EcoR V* (Roche) and *NcoI* (Fermentas) restriction enzymes. Confirmed clones were sequenced in the automated ABI 3130XL genetic analyzer to confirm the construction sequence by universal T7 and SP6 primers (BigDye Terminator V3.1 cycle Sequencing Kit). Sequencing result was analyzed by BLAST software.

Results

Analysis of rotavirus RNA segments

Rotavirus was concentrated and partially purified by ultra-centrifugation on 40% sucrose cushion at 20,000 rpm for 1 h. Fig 1 shows partially purified rotavirus which was used for RNA extraction. The virus was disrupted by either direct treatment with lysis mix (loading buffer) and briefly heating at 100⁰ C or in some cases RNA was extracted by phenol chloroform extraction method. In both cases RNA was electrophoresed on 10% PAGE and it is shown in Fig 2, 11 bands of dsRNA was observing typical of rotavirus RNA pattern.




Fig. 1. Partially purified rotavirus prepared by negative staining technique, x90000




Fig. 2. Electrophoresis pattern of rotavirus SA 11 dsRNAs in 10% PAGE, dsRNA segments were shown by numbers.

VP7s cloning

cDNA product of rotavirus genome segment 9 was cloned into pGEM⁺-5Zf(-) vector by direct bluntend ligation (resulting plasmid called VP7s-pGEM, 3984 bp, Fig 3) and confirmed by restriction enzymes. EcoR V has two restriction sites at nucleotides 43 and 556 of VP7 gene, therefore digestion by this enzyme a 513 bp and a 3471 bp fragment were obtained. The Nco I enzyme has two restriction sites at recombinant VP7s-pGEM, one at nucleotide 187 of VP7, and one at nucleotide 37 of pGEM. Therefore a 230 bp (very pale to see) and a 3740 bp fragments resulted from VP7s-pGEM by Nco I digestion.

Sequencing

The clone identified by restriction digestion was subjected to DNA sequencing in the automated ABI 3130XL genetic analyzer to confirm the sequence fidelity of VP7 -pGEM by universal T7 and SP6 primers (BigDye Terminator V3.1 cycle Sequencing Kit). Sequencing result was analyzed by BLAST that had about 100% homology with SA11 rotavirus genome segment 9 in NCBI GeneBank (2).

Discussion

The importance of rotavirus as causative agents of gastroenteritis in both young human and animals is well documented (13). Attempts have been made to control and perhaps




Fig. 3. Map of Recombinant VP7s-pGEM plasmid and its RE digestion sites.

eliminate mortality due to rotavirus infection by developing and implementing an effective vaccine (7). These developments include making live virus vaccine (14), subunits and other kind of vaccines (5). However, there have been major problems in using these vaccines for prevention of rotavirus gastroenteritis (7). The ideal goal would be to use a vaccine which is effective for protection and has no or minimum side effects (14). We have tried to prepare rotavirus proteins which are involved in virus attachment and neutralization, namely VP4 and VP7.

Our cloning method was simpler than older strategies with the same result, such as in vitro mRNA synthesis using endogenous transcriptase in viral core or using terminal riboadenylate transferase for synthesis of template for full-length cDNA synthesis (2, 4) and this is because of new progress in methodology such as RT-PCR today. Our work confirms nucleotide sequences of gene 9 after long and continuous passage of SA11 rotavirus in our laboratory; however, comparison of our obtained sequence reveals that it has been highly conserved. We omitted 3' and 5' non-coding nucleotides from cloned gene, because we want the VP7 gene to be closer to the

promoter of appropriate expression vector in future.

This work will be continued to express VP7 in future and will be studied VP7. With large scale expression and purification of VP7 protein, it will be convenient to study VP7 antigenic, immunogenic and biologic functions, which may help for development of an effective vaccine.

Acknowledgements

We would like to thank virology department of Iran University of medical sciences for their financial support and national research center of genetic engineering and biotechnology for their technical assistance.

References

1. Arias CF, Ballado T, Plebanski M. synthesis of the outer-capsid glycoprotein of the simian rotavirus SA11 in *Escherichia coli*. *Gene*. 1986;47:211-219.
2. Arias CF, Lopez S, Bell JR, Strauss IH. Primary structure of the neutralization antigen of simian rotavirus SA11 as deduced from cDNA sequence. *J. Virol.* 1984;50:657-661.
3. Blutt SE, Crawford SE, Warfield KL, Lewis DE, Estes MK, Conner ME. The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. *J. of Virology*. 2004;78:6974-6981.
4. Both GW, Mattick S, Bellamy AR. Serotype specific glycoprotein of Simian 11 rotavirus: coding assignment and gene sequence. *Proc. Natl. Acad. Sci. USA*. 1983;80:3091-3095.
5. Conner ME, Zarley CD, Hu B, Parsms S. Virus-like particles as a rotavirus subunit vaccine. *The journal of infectious diseases*. 1996;174:S88-92.
6. Estes MK. Rotaviruses and their replication, p. 1747-1785. In D. M. Knipe (ed.). *Fields virology*. 2001; 4th ed, vol. 2. Lippincott William and Wilkins, Philadelphia.
7. Favacho AR, Kurtenbach E, Silva S, Gouvea VS. Cloning, expression and purification of recombinant bovine rotavirus hemagglutinin, VP8*, in *Escherichia coli*. *Protein Expression & Purification*. 2006;46:196-203.
8. Fiore L, Dunn SJ, Ridolfi B, Ruggeri FM, Mackow ER, Greenberg HB. Antigenicity, immunogenicity and passive protection induced by immunization of mice with baculovirus-expressed VP7 protein from rhesus rotavirus. *J Gen Virol*. 1995;76(8):1981-8.
9. Johnson MA, Misra RM, Lardelli M, Messina M, Ephrussi C, Reeves PR, Bolcevic Z, Noel JS, Hum CP, Van Mai H, Dyall-Smith ML, Holmes H. Synthesis in *Escherichia coli* of the major glycoprotein of human rotavirus: analysis of the antigenic regions. *Gene*. 1989;84:73-81.
10. Kapikian AZ, Hoshino Y, Chanok RM. Rotaviruses. 2000;1787-1833.
11. Knipe DM. *Fields virology*, 4th ed ed, vol. 2. Lippincott William and Wilkins, Philadelphia.
12. Mandel, M., and A Higa. 1970. Calcium-dependent bacteriophage DNA infection. *J. Mol. Biol* 53: 159-162.
13. McGonigal TP, Turon MC, Komar-Hartnett, S, Kister E, Smith RE. Expression of the gene coding for the major outer capsid protein of SA-II rotavirus in a baculovirus system. *Virus Res*. 1993;23:135-50.
14. Parashar UD, Barese S, Gentch R, Glass R. Rotavirus. *Emerging infectious disease*. 1998;4:561-570.
15. Peixoto C, Sousa MF, Silva AC, Carrondo MT, Alves PM. Downstream processing of triple layered rotavirus like particles. *Journal of Biotechnology*. 2007;127:452-461.
16. Pro mega. 2005. Technical bulletin no 068.